Results 61 to 70 of about 86,629 (276)

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy

Experimental Hematology & Oncology, 2012
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation.
Jeter Ashley, Kang Yubin
doaj   +1 more source

Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. [PDF]

PLoS ONE, 2012
Bortezomib, a novel proteasome inhibitor approved for the treatment of cancer in adults, has recently been introduced in pediatric clinical trials. Any tissue-specific side effects on bone development have to our knowledge not yet been explored.
Emma Eriksson, Farasat Zaman, Dionisios Chrysis, Henrik Wehtje, Terhi J Heino, Lars Sävendahl   +5 more
doaj   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

Advanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang   +12 more
wiley   +1 more source

Modern strategies in therapy of elderly patients with multiple myeloma

Онкогематология, 2022
We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old.
S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova   +22 more
doaj  

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

Haematologica, 2008
Background Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex.
Enrique Colado, Stela Álvarez-Fernández, Patricia Maiso, Jesús Martín-Sánchez, Maria Belén Vidriales, Mercedes Garayoa, Enrique M. Ocio, Juan Carlos Montero, Atanasio Pandiella, Jesús F. San Miguel   +9 more
doaj   +1 more source

The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction [PDF]

, 2016
Gene therapy has long been regarded as a promising treatment for cancer. However, cancer gene therapy is still facing the challenge of targeting gene delivery vectors specifically to tumors when administered via clinically acceptable non-invasive ...
Albahrani, M, Bentayebi, K, Hajitou, A, Przystal, J, Suwan, K, Tsafa, E   +5 more
core   +2 more sources

OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα

Advanced Science, EarlyView.
This study elucidates a novel mechanistic role of the deubiquitinase OTUD6A in asthma pathogenesis, uncovering its regulatory function in airway inflammation and airway remodeling through the stabilization of hResistin/mRELMα. This study offers a novel regulatory axis (OTUD6A‐hResistin/mRELMα) in asthma pathogenesis and OTUD6A inhibition as a potential
Weiting Pan, Xinru Xi, Wei Dai, Tingfang Xiao, Yeqing Chen, Xuanyu Chen, Xiangting Ge, Chengguang Zhao, Hui Zhang, Yali Zhang, Weixi Zhang   +10 more
wiley   +1 more source

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

BMC Cancer, 2018
Background Interactions between the protein synthesis inhibitor homoharringtonine (HHT) and the proteasome inhibitor bortezomib were investigated in DLBCL and mantle cell lymphoma cells (MCL).
Tri Nguyen, Rebecca Parker, Yu Zhang, Elisa Hawkins, Maciej Kmieciak, William Craun, Steven Grant   +6 more
doaj   +1 more source

Integrated Microfluidic Platform for High‐Throughput Generation of Intestinal Organoids in Hydrogel Droplets

Advanced Science, EarlyView.
ABSTRACT Organoid research offers valuable insights into human biology and disease, but reproducibility and scalability remain significant challenges, particularly for epithelial organoids. Here, we present an integrated microfluidic platform that addresses these limitations by enabling high‐throughput generation of uniform hydrogel microparticles ...
Barbora Lavickova, Hannah Kronabitter, Mar Cervera‐Negueruela, Eylul Ceylan, Laura Benito‐Zarza, Rubén López‐Sandoval, Irineja Cubela, J. Gray Camp, Jose L. Garcia‐Cordero   +8 more
wiley   +1 more source

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair

Frontiers in Cell and Developmental Biology
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by the abnormalities of various molecules and microenvironments. Exploring these resistance mechanisms will improve the therapeutic efficacy of bortezomib.
Siyi Jiang, Lili Gao, Jian Li, Fangrong Zhang, Yanan Zhang, Jing Liu   +5 more
doaj   +1 more source